United States Continuous Glucose Monitoring Market Size & Forecast 2025–2033

The United States Continuous Glucose Monitoring (CGM) Market is on track for a transformative decade. According to Renub Research, the market is expected to expand from US$ 2.05 billion in 2024 to US$ 4.23 billion by 2033, marking an impressive CAGR of 8.36% during the forecast period of 2025–2033. This rapid rise is driven by the escalating burden of diabetes, major leaps in CGM innovation, widespread awareness about glucose control, and the expansion of insurance coverage across private and public payers.

Once considered a niche tool for Type 1 diabetes patients, CGM is now embraced across broad demographics—including Type 2 insulin users, technology-savvy individuals focused on wellness, and healthcare providers seeking better patient data. The United States, with its advanced healthcare ecosystem and burgeoning digital health movement, remains the world’s most influential CGM market.

Download Free Sample Report

United States Continuous Glucose Monitoring Market Overview

Continuous Glucose Monitoring (CGM) represents a major step forward in diabetes care. Unlike conventional finger-stick glucometers that offer only snapshots of blood sugar levels, CGM devices provide real-time, continuous tracking of glucose throughout the day and night. A tiny sensor placed beneath the skin measures interstitial glucose every few minutes, transmitting data to a smartphone, dedicated reader, or smartwatch.

This technology paints a dynamic picture of glucose fluctuations, enabling patients and clinicians to take proactive measures to prevent hyperglycemia, hypoglycemia, and long-term complications. CGM adoption has accelerated significantly in the United States due to several key factors:

Rising rates of both Type 1 and Type 2 diabetes

Expanded insurance and Medicare coverage

Technological advances by leaders including Dexcom, Abbott, and Medtronic

Digital health ecosystems enabling remote monitoring and virtual care

Growing patient preference for wearables and wellness tech

As CGMs become more accurate, discreet, and integrated with insulin pumps, smartphones, and AI-enabled platforms, they are reshaping America’s diabetes management landscape.

Key Growth Drivers in the U.S. CGM Market

1. Rising Prevalence and Earlier Diagnosis of Diabetes

The United States faces a diabetes epidemic, with over 38 million Americans diagnosed and millions more undiagnosed or prediabetic. This growing patient population is the foundation of nationwide CGM demand.

Public health programs, mass awareness campaigns, and preventive initiatives in schools, workplaces, and communities have significantly increased screening rates. Early diagnosis has become a national healthcare priority—prompting clinicians to recommend CGM as soon as glucose management becomes essential.

For patients with Type 1 diabetes, CGMs have practically become the standard of care due to their ability to minimize acute glycemic events. Meanwhile, insulin-dependent Type 2 patients increasingly rely on CGM for daily glucose insights, improving medication adherence and lifestyle decisions.

By enabling more precise glycemic control, CGMs reduce complications such as neuropathy, retinopathy, kidney disease, and hospitalizations, creating a strong economic incentive for payers and healthcare systems to support widespread CGM use.

2. Technological Innovation and Wearable Integration

The last few years have ushered in a wave of breakthroughs in CGM technology. Device accuracy, wear duration, ease of use, and connectivity have improved substantially, strengthening patient trust and provider adoption.

Notable innovations include:

Factory-calibrated sensors requiring no finger-stick calibration

Extended sensor wear of 10–14 days

Smartphone and smartwatch compatibility

Real-time alerts for high or low glucose

Bluetooth-enabled transmitters with long battery life

Integration with insulin pumps for advanced closed-loop systems

Industry leaders are driving this innovation wave. Dexcom’s G7 system and Abbott’s FreeStyle Libre 3 are among the most widely used in the U.S., while Medtronic continues to advance hybrid closed-loop technology.

In June 2024, Abbott gained FDA approval for two over-the-counter CGM systems—Lingo™ and Libre Rio™—expanding CGM availability beyond diabetes care and into the wellness market.

Wearable tech adoption is soaring in the U.S., and CGM fits perfectly into this ecosystem. As consumers flock to smartwatches, fitness trackers, and health apps, CGM becomes an appealing extension of personal health tracking.

3. Expanding Insurance Coverage and Supportive Government Policies

One of the biggest accelerators of CGM adoption has been the significant expansion of insurance reimbursement:

Medicare now covers CGMs for a wider pool of diabetes patients, including those using basal insulin.

Medicaid programs in multiple states have added CGM to their approved device lists.

Commercial insurers offer comprehensive CGM coverage thanks to compelling clinical data.

With diabetes affecting an aging population, Medicare’s coverage expansion in particular has dramatically widened access.

Post-pandemic healthcare policies emphasizing remote monitoring, telehealth, and decentralized care have also bolstered CGM’s importance. CGM data can be easily shared with physicians, allowing continuous oversight without frequent clinic visits.

Together, these policy trends position CGM as an essential pillar of chronic disease management in the U.S.

Challenges Impacting the United States CGM Market

1. High Upfront and Ongoing Costs

Despite improvements in insurance coverage, affordability remains a major barrier for many American households. CGM devices such as Dexcom G7 or FreeStyle Libre 3 require:

Initial device purchase

Recurring sensor replacements

Optional transmitter upgrades

For uninsured or underinsured patients, these costs accumulate quickly. Even with insurance, high deductibles and co-pays affect uptake. Unless long-term subsidies, pricing reforms, or new competition emerge, this challenge may limit CGM penetration in lower-income communities.

2. User Compliance and Data Overload

CGMs deliver a wealth of information, but not all users feel confident interpreting this data. Common issues include:

Alarm fatigue from frequent alerts

Misinterpretation of trend arrows

Frustration with adhesive-related skin reactions

Difficulty navigating mobile apps

Resistance among elderly or non-tech-savvy patients

Healthcare providers often recommend structured education programs to maximize CGM benefits. Simplified interfaces, better onboarding, and more intuitive data visualization will be key to improving long-term compliance.

United States CGM Market by Component

1. CGM Sensors

Sensors form the core of CGM technology and represent the largest market segment. Modern CGM sensors offer high biocompatibility, improved accuracy, and long wear time (up to 14 days). Market leaders such as Abbott and Dexcom dominate this segment with discreet, disposable, factory-calibrated sensors.

Ongoing R&D focuses on:

Reducing sensor size

Enhancing wear comfort

Improving interoperability with pumps and apps

Sensor innovation will remain a key engine driving market expansion.

2. CGM Transmitters

Transmitters send glucose data from sensors to connected devices. The U.S. market is shifting toward Bluetooth-enabled, compact, reusable transmitters with improved power efficiency. These devices support real-time monitoring, remote consultations, and integration with telehealth platforms.

Next-generation transmitters enhance:

Interoperability

User experience

Data analytics features

They also play a critical role in the evolution of artificial pancreas systems.

3. Receivers

While many patients prefer using their smartphones to receive CGM data, dedicated receivers remain relevant for users without compatible mobile devices or those seeking simplified access.

Receivers remain an important product segment, particularly among elderly patients and clinical users.

United States CGM Market by End User

1. Hospitals

Hospitals increasingly deploy CGMs to manage inpatient diabetes, surgical recovery, and emergency care. CGM helps prevent acute glucose events and reduces monitoring burden on nursing staff. Many U.S. hospitals are integrating CGM into ICU and procedural care protocols.

2. Homecare Settings

The homecare segment is the fastest-growing, driven by:

Rising telehealth adoption

Patient preference for self-monitoring

Ease of data sharing

Insurance coverage for at-home CGM use

Home-based CGM systems help reduce hospitalizations and improve long-term outcomes.

3. Others

Clinics, specialty diabetes centers, and ambulatory care facilities also contribute significantly to CGM adoption in the U.S.

Top 10 States Leading the U.S. CGM Market

California – A hub for med-tech innovation and digital health adoption

Texas – Large diabetes population and expanding healthcare facilities

New York – Strong hospital networks and high consumer health-tech adoption

Florida – High elderly population with rising CGM use

Illinois – Robust medical infrastructure and strong payer support

Pennsylvania – Growing clinical adoption across hospitals and homecare

Ohio – Broad-based telehealth utilization and diabetes prevalence

Georgia – Increasing healthcare access and remote monitoring solutions

Washington – Strong digital health foundation and chronic care initiatives

New Jersey – Dense healthcare networks and pharma presence

The “Rest of the United States” category also shows steady growth due to improving awareness and digital health integration across rural and suburban regions.

Key Players in the United States CGM Market

All companies are covered with five viewpoints: Overview, Key Person, Recent Developments, SWOT, and Revenue Analysis.

Major companies include:

Abbott Laboratories

DexCom Inc.

Medtronic Plc.

Roche

Senseonics Holdings, Inc.

Tandem Diabetes Care

Ypsomed Holding AG

i-Sens Inc.

These players collectively drive market expansion through innovation, partnerships, regulatory approvals, and expanded distribution networks.

Final Thoughts

The United States Continuous Glucose Monitoring Market is entering a new era—one defined by innovation, accessibility, and data-driven care. As diabetes prevalence continues to rise, CGM offers a lifeline to millions of Americans seeking better control, fewer complications, and improved quality of life.

With expanding insurance coverage, rapid technological progress, and growing adoption across hospitals and homecare, the CGM market will remain one of the most dynamic sectors in U.S. healthcare. From California to New York, demand is accelerating, and the next decade promises more integration, more affordability, and smarter diabetes management.

As the nation shifts toward personalized, preventive healthcare, CGM stands out as a transformative tool—ushering in a future where real-time, connected monitoring becomes the norm rather than the exception.